Cargando…

Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study

The objective of the present investigation was to enhance the oral bioavailability of practically insoluble Candesartan cilexetil [CC] by preparing nanosuspension. The nanosuspension was prepared by media milling using zirconium oxide beads and converted to solid state by spray drying. The spray dri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Detroja, Chetan, Chavhan, Sandip, Sawant, Krutika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Österreichische Apotheker-Verlagsgesellschaft 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163369/ https://www.ncbi.nlm.nih.gov/pubmed/21886909 http://dx.doi.org/10.3797/scipharm.1103-17

Ejemplares similares

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions
por: Tjandrawinata, Raymond R, et al.
Publicado: (2013)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion
por: Kamalakkannan, V, et al.
Publicado: (2013)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Chemometric Methods for Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide in Binary Combinations
por: Ali, Diyar Salahuddin
Publicado: (2023)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
por: Figueroa-Campos, Andrés, et al.
Publicado: (2020)

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration
por: Anwar, Walid, et al.
Publicado: (2020)

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
por: Mengden, Thomas, et al.
Publicado: (2009)

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model
por: Ghafil, Fadhaa Abdulameer, et al.
Publicado: (2022)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
por: Poudel, Surendra, et al.
Publicado: (2021)

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2020)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets
por: Belal, Tarek S., et al.
Publicado: (2013)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model
por: YAN, WEN-HUA, et al.
Publicado: (2016)

Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
por: Féghali, Ramzi EL, et al.
Publicado: (2007)

A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
por: Kumar, Namala Durga Atchuta, et al.
Publicado: (2012)

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
por: Chang, Gwo‐Jyh, et al.
Publicado: (2022)

Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation
por: Nakarani, M., et al.
Publicado: (2010)

Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
por: Nakarani, Mahendra, et al.
Publicado: (2010)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
por: Rakugi, Hiromi, et al.
Publicado: (2012)

Formulation and characterization of Cefuroxime Axetil nanoemulsion for improved bioavailability
por: Patel, Yomesh, et al.
Publicado: (2012)

Formulation Strategies of Nanosuspensions for Various Administration Routes
por: Pınar, Sıla Gülbağ, et al.
Publicado: (2023)

Candesartan Cilexetil Improves Angiotensin II Type 2 Receptor–Mediated Neurite Outgrowth via the PI3K-Akt Pathway in Fructose-Induced Insulin-Resistant Rats
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2012)

Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
por: Ibrahim, Mohamed A., et al.
Publicado: (2019)

Floating microspheres of valacyclovir HCl: Formulation, optimization, characterization, in vitro and in vivo floatability studies
por: Goswami, Nilamgiri, et al.
Publicado: (2012)

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement
por: Thakkar, Hetal Paresh, et al.
Publicado: (2011)

Enhancement of oral bioavailability of quercetin by metabolic inhibitory nanosuspensions compared to conventional nanosuspensions
por: Li, Haowen, et al.
Publicado: (2021)

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
por: Wang, Yonglu, et al.
Publicado: (2011)

Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery
por: Chiang, Po-Chang, et al.
Publicado: (2011)

Physicians’ Attitudes towards and Reasons for Participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial
por: Rahman, Mahbubur, et al.
Publicado: (2005)

Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay
por: Kim, Ji Won, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ubl3gsrkbnuva3va1gvu3c3d21